机构:[1]State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China[2]Department of Endocrinology, Genetics and Metabolism, National Center for Children’s Health, Beijing Children’s Hospital, Capital Medical University, Beijing 100045, China首都医科大学附属北京儿童医院[3]Department of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China内科系统心脏科(内科专业)首都医科大学宣武医院[4]Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China首都医科大学附属安贞医院
Background Although non-invasive liver fibrosis scores (LFSs) have already been considered as effective tools for estimating cardiovascular risk, their roles in predicting disease severity and cardiovascular event (CVEs) in patients with stable coronary artery disease (CAD) are not comprehensively evaluated. The aim of the present study was to investigate whether non-alcoholic fatty liver disease fibrosis score (NAFLD-FS) and fibrosis-4 (FIB-4) are associated with CVEs in a large cohort with long-term follow-up. Methods A cohort of 5143 patients with angiography-proven stable CAD were consecutively enrolled and followed up for CVEs. The degree of coronary severity was assessed using the number of diseased vessels, Gensini, Syntax, and Jeopardy scores. The predictive values of NAFLD-FS and FIB-4 scores to coronary severity, coronary calcification (CAC), and CVEs were assessed, respectively. Results During a median follow-up of 7 years, 435 CVEs were recorded. Both NAFLD-FS and FIB-4 were predictors for the presence of CAC. The degree of coronary stenosis was significantly higher in high NAFLD-FS categories while FIB-4 was only positively associated with the number of diseased vessels and Gensini score. In Kaplan-Meier analysis, the patients with intermediate and high NAFLD-FS and FIB-4 had higher risk of CVEs and cardiovascular mortality. In multivariate Cox regression analysis, NAFLD-FS and FIB-4 were independently associated with CVEs [hazard ratio (95% confidence interval): 1.150 (1.063-1.244), p < 0.001 and 1.128 (1.026-1.240), p = 0.012]. Conclusion The current data first indicated that both NAFLD-FS and FIB-4 scores were not only significantly related to coronary severity but also associated with CAC and CVEs. Background Although non-invasive liver fibrosis scores (LFSs) have already been considered as effective tools for estimating cardiovascular risk, their roles in predicting disease severity and cardiovascular event (CVEs) in patients with stable coronary artery disease (CAD) are not comprehensively evaluated. The aim of the present study was to investigate whether non-alcoholic fatty liver disease fibrosis score (NAFLD-FS) and fibrosis-4 (FIB-4) are associated with CVEs in a large cohort with long-term follow-up. [GRAPHICS] .
基金:
Capital Health Development Fund [201614035]; CAMS Major Collaborative Innovation Project [2016-I2M-1-011]
第一作者机构:[1]State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China[2]Department of Endocrinology, Genetics and Metabolism, National Center for Children’s Health, Beijing Children’s Hospital, Capital Medical University, Beijing 100045, China
通讯作者:
推荐引用方式(GB/T 7714):
Jin Jing-Lu,Zhang Hui-Wen,Cao Ye-Xuan,et al.Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease[J].HEPATOLOGY INTERNATIONAL.2021,15(2):413-423.doi:10.1007/s12072-021-10167-w.
APA:
Jin, Jing-Lu,Zhang, Hui-Wen,Cao, Ye-Xuan,Liu, Hui-Hui,Hua, Qi...&Li, Jian-Jun.(2021).Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease.HEPATOLOGY INTERNATIONAL,15,(2)
MLA:
Jin, Jing-Lu,et al."Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease".HEPATOLOGY INTERNATIONAL 15..2(2021):413-423